Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) have received an average recommendation of “Buy” from the twenty-one research firms that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and fourteen have given a buy rating to the company. […]
Equities research analysts expect that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) will report earnings of $9.91 per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for Regeneron Pharmaceuticals’ earnings, with estimates ranging from $8.07 to $11.10. Regeneron Pharmaceuticals posted earnings of $25.80 per share during the same […]
Wall Street brokerages forecast that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) will report earnings of $9.37 per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Regeneron Pharmaceuticals’ earnings. The lowest EPS estimate is $8.49 and the highest is $10.93. Regeneron Pharmaceuticals posted earnings per share of $9.89 […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) had its target price upped by investment analysts at Cowen from $640.00 to $645.00 in a note issued to investors on Wednesday, Stock Target Advisor reports. Cowen’s price objective would suggest a potential downside of 10.25% from the stock’s previous close. REGN has been the subject of a number […]
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) Director Bonnie L. Bassler sold 1,240 shares of the firm’s stock in a transaction that occurred on Thursday, April 7th. The shares were sold at an average price of $725.00, for a total transaction of $899,000.00. Following the completion of the sale, the director now directly owns 1,082 […]